July 29th 2025
Oncology nurses can ensure patients with non–small cell lung cancer receive the optimal treatment quickly by understanding comprehensive genomic profiling.
FDA Approves Amivantamab Plus Chemo Combo for Advanced NSCLC With EGFR Exon 20 Insertion Mutations
March 1st 2024Amivantamab was approved by the FDA as first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations or as therapy for those whose disease progressed on or after platinum-based chemotherapy.
Perioperative Tislelizumab Plus Chemo Improves Event-Free Survival in Resectable NSCLC
March 1st 2024Treatment with neoadjuvant tislelizumab plus platinum-based doublet chemotherapy, followed by surgery and adjuvant tislelizumab, improved event-free survival in patients with resectable non–small cell lung cancer.
SBRT Plus Standard of Care Improves PFS in Oligoprogressive NSCLC
February 19th 2024Stereotactic ablative radiotherapy with standard-of-care therapy improved progression-free survival in patients with oligoprogressive non-small cell lung cancer, although the benefit was not seen in those with oligoprogressive breast cancer.
Tislelizumab Plus Chemo Improves Event-Free Survival in Stage II-IIIA NSCLC
February 17th 2024The use of perioperative tislelizumab plus neoadjuvant chemotherapy has been supported by findings from the phase 3 RATIONALE-315 study as a treatment for resectable stage II to IIIA non–small cell lung cancer.
Osimertinib Receives Approval From FDA for EGFR-Mutated Locally Advanced or Metastatic NSCLC
February 16th 2024The FDA approved osimertinib for use with platinum-based chemotherapy to treat patients with locally advanced or metastatic non-small cell lung cancer that harbor EGFR exon 19 deletions or exon 21 L858R mutations.
Sacituzumab Govitecan Did Not Provide OS Benefit in Pretreated NSCLC
January 29th 2024Researchers determined that the phase 3 EVOKE-01 trial failed to meet its primary end point of significantly improved OS with sacituzumab govitecan in patients with pretreated non-small cell lung cancer compared with docetaxel.
LUMINANCE Study Supports Durvalumab Plus Platinum/Etoposide in Frontline Treatment of ES-SCLC
January 10th 2024Findings from the phase 3b LUMINANCE study aligned with safety and efficacy outcomes from the phase 3 CASPIAN trial, both of which focused on the administration of 5 or more cycles of induction platinum/etoposide alongside durvalumab for the treatment of patients with extensive-stage small cell lung cancer.
Lenvatinib-Pembrolizumab Combo May Not Improve Survival vs. Docetaxel in Stage IV NSCLC
January 9th 2024A survival advantage via treatment with lenvatinib plus pembrolizumab was not seen when compared with docetaxel for advanced-stage non–small cell lung cancer whose disease progressed after previous exposure to a PD-L1 inhibitor and platinum-based chemotherapy.
Tremelimumab/Durvalumab Plus Chemo Improves Survival in Metastatic NSCLC
January 8th 2024Adding a limited course of tremelimumab to frontline durvalumab and chemotherapy may provide patients with previously untreated metastatic non-small cell lung cancer a sustained overall survival benefit compared with chemotherapy alone.